ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

TyboWe® Adalimumab Injection

Its studies are mostly in Crohn Disease · Uveitis, led by Sino Biopharmaceutical.

Furthest: phase 4, since Jun 17, 20262 company-led studies, 2 open or runningNext primary completion: Feb 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical22 open or runningphase 4since Jun 17, 2026Jun 17, 2026Feb 2028phase 4 · NCT07663331

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 17, 2026First studies: 2 phase 4 studiesFirst studyNCT07663526, NCT07663331

Ahead

  1. Feb 2028Primary completion: phase 4 study in Adult Non-infectious UveitisNCT07663331
  2. Dec 2028Primary completion: phase 4 study in Crohn DiseaseNCT07663526

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07663331Adult Non-infectious Uveitis · China4RecruitingFeb 202830
NCT07663526Crohn Disease · China4RecruitingDec 202850

How it is read

Names in the registry

  • “TyboWe® Adalimumab Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.